香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由榮昌生物製藥 （煙台）股份有限公司（「本公司」）作出。 茲載列本公司於上海證券交易所網站刊登公告如下，僅供參閱。 承董事會命 榮昌生物製藥（煙台）股份有限公司 董事長兼執行董事 王威東先生 中國煙台 2026年3月27日 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 海外監管公告 公司代码：688331 公司简称：荣昌生物 荣昌生物制药（烟台）股份有限公司 2025 年年度报告摘要 荣昌生物制药（烟台）股份有限公司 2025 年年度报告摘要 第一节 重要提示 1、 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 於本公告日期，董事會成員包括執行董事王威東先生、房健民博士、林健先生及 溫慶凱先生； ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由榮昌生物製藥 （煙台）股份有限公司（「本公司」）作出。 茲載列本公司於上海證券交易所網站刊登公告如下，僅供參閱。 承董事會命 榮昌生物製藥（煙台）股份有限公司 董事長兼執行董事 王威東先生 中國煙台 2026年3月27日 於本公告日期，董事會成員包括執行董事王威東先生、房健民博士、林健先生及 溫慶凱先生；非執行董事王荔強博士及蘇曉迪博士；及獨立非執行董事郝先經先 生、陳雲金先生及黃國濱先生。 * 僅供識別 荣昌生物制药（烟台）股份有限公司 2025 年年度报告 公司代码：688331 公司简称：荣昌生物 荣昌生物制药（烟台）股份有限公司 2025 年年度报告 1 / 2 ...

Core Viewpoint - The company is a global innovative biopharmaceutical enterprise focused on the discovery, development, and commercialization of antibody-based therapies, aiming to address unmet clinical needs in various disease areas, including autoimmune diseases and cancers [2][3][29]. Company Overview - The company specializes in antibody-drug conjugates (ADC), antibody fusion proteins, and monoclonal antibodies, targeting first-in-class and best-in-class biopharmaceuticals to provide effective clinical solutions [2][3]. - The company has established three R&D centers in Yantai, Shanghai, and California, focusing on preclinical development and clinical trials [26]. Research and Development Pipeline - The company has a robust R&D pipeline, including products like RC18 (Tai'aisip), a first-in-class dual-target fusion protein for autoimmune diseases, and RC48 (Vidisicimab), an ADC targeting HER2 for various cancers [3][13]. - As of the reporting period, RC148, a bispecific antibody targeting PD-1 and VEGF, has received breakthrough therapy designation for non-small cell lung cancer (NSCLC) [24]. Product Progress - Tai'aisip has received conditional approval for systemic lupus erythematosus, myasthenia gravis, and rheumatoid arthritis in China, with ongoing clinical trials for additional indications [4][5][8]. - Vidisicimab has shown promising results in clinical trials for bladder cancer and gastric cancer, achieving high objective response rates and significant survival benefits compared to traditional therapies [15][17][20]. Industry Context - The biopharmaceutical industry is characterized by continuous breakthroughs in biotechnology, leading to the development of targeted therapies that address previously untreatable diseases [29]. - The industry is experiencing growth driven by advancements in drug discovery capabilities and the increasing demand for innovative treatments [29].

Group 1 - The application for injectable Aloxacillin Sodium by Xinhua Pharmaceutical (Gaomi) Co., Ltd. has been accepted, with acceptance number CYHB2600593, on March 26, 2026 [1][3] - The drug type is classified as a chemical drug, and the application type is a supplementary application [2][4] - The company was established on December 29, 2000, and is a small-sized limited liability company in the biopharmaceutical manufacturing industry, with a registered capital of 19 million RMB [5] Group 2 - The legal representative of Xinhua Pharmaceutical (Gaomi) Co., Ltd. is Xu Wenhui, and the company has 239 insured employees [5] - The sole shareholder is Shandong Xinhua Pharmaceutical Co., Ltd., holding 100% of the shares with a subscribed capital of 19 million RMB [5]

Core Viewpoint - The application for Roxithromycin suspension by Xinhua Pharmaceutical (Gaomi) Co., Ltd. has been accepted by the National Medical Products Administration on March 26, 2026, with acceptance number CYHB2600592 [1][3]. Company Information - Company Name: Xinhua Pharmaceutical (Gaomi) Co., Ltd. [2][5] - Established Date: December 29, 2000 [5] - Legal Representative: Xu Wenhui [5] - Industry: Biopharmaceutical Manufacturing [5] - Company Type: Limited Liability Company (non-natural person investment or holding) [5] - Company Size: Small [5] - Number of Employees: 239 [5] - Registered Capital: 19 million RMB [5] - Paid-in Capital: 19 million RMB [5] - Registered Address: No. 6, West High-tech Industrial Development Zone, Gaomi City, Weifang, Shandong Province [5]. Shareholder Information - Shareholder: Shandong Xinhua Pharmaceutical Co., Ltd. [5] - Shareholding Ratio: 100% [5] - Contributed Capital: 19 million RMB [5] - Contribution Date: May 10, 2012 [5] - First Shareholding Date: April 11, 2012 [5].

Group 1 - In 2025, China's high-tech industry sales revenue is expected to grow by 13.9%, with lithium-ion batteries, integrated circuits, and biopharmaceutical manufacturing experiencing sales growth of 25.1%, 19.2%, and 7.7% respectively [1] - The national supply and marketing cooperative system is set to conduct agricultural social services covering 3.5 million acres in 2025, promoting cost reduction and stable grain production [2] - Germany's trade with China is projected to reach €253 billion in 2025, marking a year-on-year increase of approximately 2.7%, reaffirming China as Germany's largest trading partner [2] Group 2 - The number of cross-regional personnel movements during the Spring Festival is reported to be 222.51 million, reflecting a month-on-month increase of 5.3% and a year-on-year increase of 3.9% [2] - The Central Meteorological Administration has issued a blue wind warning, predicting strong winds in various regions, including parts of Xinjiang, Inner Mongolia, and the East China Sea [3] - The Macau Special Administrative Region reported a record daily entry and exit flow of 867,000 people, with the Gongbei Port seeing nearly 463,000, the highest in five years [1]

Group 1 - The application for Ipilimumab injection by Bristol-Myers Squibb Holdings Pharma, Ltd. has been accepted, with acceptance number JTS2600018, on February 7, 2026 [1] - Ipilimumab is classified as a biological product and is being registered for import [1] - Shanghai Junshi Biosciences Co., Ltd. is a key player in this application, alongside Bristol-Myers Squibb [1] Group 2 - Shanghai Junshi Biosciences Co., Ltd. was established on June 26, 2014, and is a medium-sized foreign-invested enterprise with a registered capital of 74 million RMB [1] - The company has 774 insured employees and is located at 1289 Yishan Road, Xuhui District, Shanghai [1] - The sole shareholder of Shanghai Junshi Biosciences is Junshi Biosciences Co., Ltd., which holds 100% of the shares [1]

Core Viewpoint - The company announced that its major shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., has released a pledge on 18.6 million shares, which represents 14.82% of its holdings and 1.67% of the company's total share capital [1] Group 1 - After the release of the pledge, the shareholder holds 126 million shares, accounting for 11.29% of the total share capital [1] - The remaining pledged shares amount to 15.82 million, which is 12.60% of the shareholder's total holdings and 1.42% of the company's total share capital [1] - The combined holdings of Jinyu Biological Holdings and its concerted parties total 155 million shares, representing 13.91% of the total share capital, with a cumulative pledge of 15.82 million shares, which is 10.23% of the combined holdings [1]

Group 1 - The core viewpoint of the articles indicates that China's industrial economy is showing signs of stabilization and transformation, with a return to positive profit growth for the first time in three years, achieving a total profit of 73,982 billion yuan in 2025, a 0.6% increase from the previous year [1] - In December 2025, profits for large-scale industrial enterprises increased by 5.3%, reversing a 13.1% decline in November, indicating a significant recovery [1] - The data reflects a structural shift in China's industrial economy, with new growth drivers emerging, particularly in the equipment manufacturing and high-tech manufacturing sectors, which are becoming the main contributors to profit growth [1][2] Group 2 - The equipment manufacturing sector saw a profit increase of 7.7%, contributing 2.8 percentage points to the overall profit growth of large-scale industrial enterprises, with its profit share rising to 39.8% [1] - High-tech manufacturing profits grew by 13.3%, surpassing the overall industrial profit growth rate of 12.7%, highlighting its role in driving high-quality industrial development [1] - Key industries such as semiconductors experienced explosive profit growth, with integrated circuit manufacturing profits increasing by 172.6%, indicating the success of China's innovation-driven development strategy [2] Group 3 - Traditional industries, particularly mining, faced significant profit declines, with the mining sector's profits dropping by 26.2%, primarily due to falling international oil prices and the transition to green energy [2] - The shift in industrial competitiveness is moving from cost efficiency to technological innovation and system resilience, as evidenced by high profit growth in sectors like railways, shipbuilding, and semiconductors [3] - The growth logic of industrial enterprises is transitioning from speed and scale to quality and efficiency, with profit growth becoming more closely linked to added value rather than revenue growth [3] Group 4 - Domestic consumption and investment are still recovering, while external demand faces increased risks due to geopolitical and economic uncertainties, leading to challenges of insufficient effective demand and overcapacity in industrial enterprises [4] - Continuous efforts are needed to promote the transformation and upgrading of traditional industries, encouraging mergers, restructuring, or bankruptcy to eliminate inefficient capacity and help improve the financial health of industrial enterprises [4]

Market Overview - On January 27, the market rebounded slightly with the Shanghai Composite Index rising by 0.18%, the Shenzhen Component by 0.09%, and the ChiNext Index by 0.71%[3] - The total trading volume on January 27 was 2.92 trillion, a decrease of approximately 360 billion from the previous trading day[1] Sector Performance - The semiconductor, communication equipment, and aerospace sectors saw significant inflows, while the battery, securities, and power grid sectors experienced outflows[3] - High-tech manufacturing profits grew by 13.3% in 2025, surpassing the overall industrial profit growth of 0.6%[4][6] Profit Growth - The profit of the high-tech manufacturing sector was driven by smart electronics, which saw a 48% increase, and the semiconductor industry, which experienced profit growth of 172.6%[4] - The automotive industry reported a profit of 461 billion, reflecting a 0.6% increase year-on-year, with a profit margin of 4.1%[9] Fund Dynamics - The total income of the three social insurance funds reached 9.1 trillion, with a cumulative surplus of 10.2 trillion by the end of 2025[11] - The ETF trading volume reached 538.9 billion, with stock ETFs accounting for 244.7 billion and bond ETFs for 187.2 billion[12] Employment and Policy - The Ministry of Human Resources and Social Security announced measures to support employment in key industries affected by artificial intelligence[7] - New guidelines were issued to enhance safety equipment in industrial sectors, focusing on the elimination of outdated technologies[8]